Ariosa Diagnostics, Illumina diagnostic news
Illumina filed suit in the U.S. District Court for the Northern District of California alleging that Ariosa's Harmony Prenatal Test infringes Illumina's U.S. Patent No. 7,955,794, which covers multiplex nucleic acid reactions. In Illumina, Inc. v. Ariosa Diagnostics, Inc., Illumina said the technology underlying Harmony Prenatal Test involves a multiplexing method for detecting target sequences. Verinata Health Inc., now part of Illumina, previously sued Ariosa for infringement of U.S. Patent Nos. 8,296,076 and 8,318,430 in the U.S. District Court for the Northern District of California. The '076 patent covers non-invasive diagnosis of fetal aneuploidy by sequencing, and the '430 patent covers methods of fetal abnormality detection. Illumina said the court issued an order supporting "the position that Ariosa infringes those patents," but declined to disclose further details. Ariosa could not be reached for comment.
The Harmony Prenatal Test is a non-invasive prenatal multiplex assay that detects fetal trisomies 13, 18 and 21 in maternal plasma cell-free DNA (cfDNA). ...